Free Trial

Zenas BioPharma (ZBIO) Competitors

Zenas BioPharma logo
$19.90 +0.94 (+4.96%)
As of 11:03 AM Eastern

ZBIO vs. LGND, FOLD, MNKD, CLDX, BCRX, NVAX, INVA, DVAX, OPK, and GERN

Should you be buying Zenas BioPharma stock or one of its competitors? The main competitors of Zenas BioPharma include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry.

Zenas BioPharma vs. Its Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Ligand Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$187.58M17.91-$4.03M-$4.00-42.86
Zenas BioPharma$5M167.43-$156.99M-$3.55-5.60

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 16.5% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zenas BioPharma has a net margin of 0.00% compared to Ligand Pharmaceuticals' net margin of -40.44%. Ligand Pharmaceuticals' return on equity of -9.21% beat Zenas BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals-40.44% -9.21% -8.09%
Zenas BioPharma N/A -59.21%-50.56%

In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 1 mentions for Zenas BioPharma. Ligand Pharmaceuticals' average media sentiment score of 0.88 beat Zenas BioPharma's score of 0.67 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zenas BioPharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ligand Pharmaceuticals presently has a consensus target price of $176.50, indicating a potential upside of 2.95%. Zenas BioPharma has a consensus target price of $36.67, indicating a potential upside of 84.44%. Given Zenas BioPharma's higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Zenas BioPharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Ligand Pharmaceuticals beats Zenas BioPharma on 8 of the 14 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZBIO vs. The Competition

MetricZenas BioPharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$837.15M$3.13B$5.72B$10.40B
Dividend YieldN/A2.36%5.53%4.58%
P/E Ratio-5.6021.0076.4326.62
Price / Sales167.43255.87472.7192.34
Price / CashN/A46.3537.4661.85
Price / Book2.669.8013.276.45
Net Income-$156.99M-$52.73M$3.29B$271.39M
7 Day Performance4.25%4.70%2.60%3.06%
1 Month Performance16.26%6.23%4.65%7.62%
1 Year PerformanceN/A18.77%74.34%30.20%

Zenas BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZBIO
Zenas BioPharma
1.1125 of 5 stars
$19.90
+5.0%
$36.67
+84.3%
N/A$837.99M$5M-5.61N/AGap Up
LGND
Ligand Pharmaceuticals
4.0191 of 5 stars
$166.24
+0.4%
$176.50
+6.2%
+71.2%$3.24B$167.13M-41.5680High Trading Volume
FOLD
Amicus Therapeutics
3.9363 of 5 stars
$8.01
+3.6%
$16.00
+99.8%
-27.3%$2.38B$528.29M-66.74480High Trading Volume
MNKD
MannKind
4.297 of 5 stars
$5.37
-0.2%
$11.17
+107.9%
-17.9%$1.65B$285.50M48.82400Positive News
CLDX
Celldex Therapeutics
1.8 of 5 stars
$24.58
+0.3%
$46.67
+89.9%
-39.7%$1.63B$7.02M-8.17150
BCRX
BioCryst Pharmaceuticals
4.2741 of 5 stars
$7.75
+0.6%
$16.70
+115.5%
+0.4%$1.62B$450.71M-43.05530Positive News
NVAX
Novavax
4.2316 of 5 stars
$8.56
+5.9%
$14.29
+66.9%
-32.3%$1.31B$682.16M3.751,990
INVA
Innoviva
4.7834 of 5 stars
$19.34
-1.1%
$42.75
+121.0%
+1.0%$1.23B$358.71M62.39100Analyst Upgrade
DVAX
Dynavax Technologies
4.1913 of 5 stars
$9.70
+3.6%
$24.33
+150.9%
-13.7%$1.10B$277.25M-21.09350
OPK
OPKO Health
4.4708 of 5 stars
$1.39
+0.7%
$2.75
+97.8%
-4.0%$1.10B$713.10M-5.562,997News Coverage
GERN
Geron
2.6227 of 5 stars
$1.25
-1.6%
$3.79
+202.9%
-68.7%$810.28M$76.99M-9.6270Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ZBIO) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners